YAP1 and cancer: In a short-term assay, combining osimertinib with the K-975 TEAD inhibitor (at a single dose shown to disrupt YAP1/WWTR1 and TEAD binding) resulted in a dose-dependent and significant decrease in persister cancer cells (Fig. 5c).